Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis

Overview of attention for article published in Journal of experimental pharmacology, February 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 71 followers.

New canine paper! Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis https://t.co/S4kOjNq90T

20 Feb 2022

Reply Repost Favourite

New dog paper! Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis https://t.co/Xos84RQwXg

20 Feb 2022

Reply Repost Favourite

Dove Medical Press

Article Metrics

Non-Clinical Safety Pharmacology Evaluations of Trazpiroben (TAK-906), a Novel Dopamine D2/D3 Selective Receptor Antagonist for the Management of Gastroparesis

Mentioned by